A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301)
Pavlina Spiliopoulou(Beatson West of Scotland Cancer Centre), Sarah P. Blagden(Churchill Hospital), Lucinda Griffiths(University of Oxford), T.R. Jeffry Evans(Leiden University Medical Center), M.J. Parkes(MRC Clinical Trials Unit at UCL), Cathy Qi(MRC Clinical Trials Unit at UCL), Vicky M. Coyle(Queen's University Belfast), David J. Harrison(NHS Lothian), Jill Graham(Beatson West of Scotland Cancer Centre), Simon Lord(University of Oxford), Farasat Kazmi(University of Oxford), Gareth J. Veal(Newcastle University), Thomas W. Holmes(University of Oxford), D. J. Thompson(University of Oxford), Francesca Aroldi(Churchill Hospital)
Cited by 8
Related Papers
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
|The Lancet Oncology|2019|564
Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT)
|Journal of Clinical Oncology|2018|274
Performance status score: do patients and their oncologists agree?
|British Journal of Cancer|2003|222